Augmedix, Inc. (NASDAQ:AUGX) Insider Sells $207,089.61 in Stock

Augmedix, Inc. (NASDAQ:AUGX) insider Ian Shakil sold 51,387 shares of the company’s stock in a transaction on Friday, April 5th. The shares were sold at an average price of $4.03, for a total transaction of $207,089.61. Following the completion of the sale, the insider now directly owns 12,217 shares in the company, valued at $49,234.51. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ian Shakil also recently made the following trade(s):

• On Monday, April 8th, Ian Shakil sold 37,780 shares of Augmedix stock. The shares were sold at an average price of $3.97, for a total transaction of $149,986.60.
• On Wednesday, April 3rd, Ian Shakil sold 45,906 shares of Augmedix stock. The stock was sold at an average price of $4.11, for a total transaction of $188,673.66.
• On Monday, April 1st, Ian Shakil sold 58,978 shares of Augmedix stock. The stock was sold at an average price of $3.91, for a total transaction of $230,603.98.
• On Thursday, March 28th, Ian Shakil sold 31,994 shares of Augmedix stock. The stock was sold at an average price of $4.06, for a total transaction of $129,895.64.

Augmedix Stock Up 1.0 %

AUGX opened at $4.06 on Wednesday. Augmedix, Inc. has a twelve month low of $1.50 and a twelve month high of $6.25. The company has a quick ratio of 2.41, a current ratio of 2.41 and a debt-to-equity ratio of 0.66. The company has a 50-day moving average price of $4.17 and a 200 day moving average price of $4.85. The company has a market cap of $197.88 million, a PE ratio of -9.02 and a beta of -0.16.

Augmedix (NASDAQ:AUGX) last released its quarterly earnings results on Monday, March 18th. The company reported ($0.09) earnings per share for the quarter. Augmedix had a negative return on equity of 308.50% and a negative net margin of 42.74%. The company had revenue of $12.68 million for the quarter, compared to analyst estimates of $12.30 million. Sell-side analysts expect that Augmedix, Inc. will post -0.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Maxim Group lowered their target price on shares of Augmedix from $6.50 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, March 19th. Evercore ISI raised shares of Augmedix from an “in-line” rating to an “outperform” rating and increased their target price for the stock from $4.50 to $5.00 in a research note on Tuesday. Finally, B. Riley assumed coverage on shares of Augmedix in a research note on Wednesday, April 3rd. They set a “buy” rating and a $5.50 target price on the stock.

Institutional Trading of Augmedix

A number of hedge funds and other institutional investors have recently made changes to their positions in AUGX. Russell Investments Group Ltd. increased its holdings in shares of Augmedix by 292.0% during the 4th quarter. Russell Investments Group Ltd. now owns 891,077 shares of the company’s stock worth $5,213,000 after buying an additional 663,778 shares during the last quarter. Parkman Healthcare Partners LLC increased its holdings in shares of Augmedix by 170.1% during the 4th quarter. Parkman Healthcare Partners LLC now owns 1,015,814 shares of the company’s stock worth $5,943,000 after buying an additional 639,732 shares during the last quarter. Essex Investment Management Co. LLC acquired a new stake in shares of Augmedix during the 3rd quarter worth approximately $2,237,000. Ameriprise Financial Inc. acquired a new stake in shares of Augmedix during the 3rd quarter worth approximately $1,250,000. Finally, Legato Capital Management LLC acquired a new stake in shares of Augmedix during the 3rd quarter worth approximately $840,000. Institutional investors and hedge funds own 87.11% of the company’s stock.

Augmedix Company Profile

Augmedix, Inc provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits.